# FBXO40

## Overview
FBXO40 is a gene that encodes the F-box protein 40, a member of the F-box protein family, which is integral to the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex. This protein functions primarily as a substrate-recognition component, facilitating the ubiquitination and subsequent proteasomal degradation of target proteins, a process vital for cellular protein homeostasis (Stepanov2018Analysis). F-box protein 40 is particularly significant in muscle tissue, where it regulates the degradation of IRS1 (Insulin Receptor Substrate 1), thereby influencing insulin-like growth factor (IGF) signaling pathways that are crucial for muscle development and maintenance (Shi2011The). Additionally, FBXO40 has been implicated in neurodevelopmental processes and metabolic pathways, with potential links to conditions such as autism spectrum disorders and insulin resistance (Yang2016Role; Glessner2009Autism). The gene's expression is modulated by physical activity, suggesting a role in muscle adaptation and response to exercise (Stefanetti2014Ageing).

## Structure


## Function
FBXO40 is a member of the F-box protein family, characterized by its role as a substrate-recognition component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex. This complex is involved in targeting proteins for ubiquitination and subsequent proteasomal degradation, a critical process for maintaining protein homeostasis within cells (Stepanov2018Analysis). In healthy human cells, FBXO40 is implicated in the modulation of insulin growth factor (IGF) signaling, which is essential for normal brain development, nerve cell metabolism, and neuronal excitability. This signaling pathway plays a protective role against neuronal damage and is linked to cognitive performance and neurodegenerative processes (Stepanov2018Analysis).

FBXO40 is also involved in muscle development and maintenance, influencing protein turnover and cellular signaling pathways. It is primarily active in the cytoplasm, where it regulates the stability of specific substrates, impacting muscle cell differentiation and growth (Stefanetti2014Ageing). The gene's expression is responsive to resistance exercise, with increased mRNA levels observed in both younger and older individuals, although protein levels are generally lower in older subjects (Stefanetti2014Ageing). This suggests a role in muscle adaptation and response to physical activity.

## Clinical Significance
Mutations and alterations in the FBXO40 gene have been implicated in several clinical conditions. FBXO40 is involved in the ubiquitin-proteasome system, which is crucial for muscle development and maintenance. Knockout studies in mice and pigs have shown that the absence of FBXO40 leads to muscle hypertrophy, indicating its role in regulating muscle growth (Shi2011The; Blondelle2020The). This suggests that dysregulation of FBXO40 could contribute to muscle-related disorders.

In the context of autism spectrum disorders (ASDs), copy number variations (CNVs) in FBXO40 have been identified as significantly enriched in ASD cases. This suggests a potential role for FBXO40 in ASD susceptibility, possibly through its involvement in the ubiquitin pathway, which affects synaptic function and neuronal cell-adhesion molecules (Glessner2009Autism; Rosti2013The).

Alterations in FBXO40 expression may also impact insulin signaling pathways. FBXO40 targets IRS1 for degradation, and its dysregulation could contribute to insulin resistance, a precursor to type 2 diabetes (Yang2016Role). These findings highlight the clinical significance of FBXO40 in various conditions related to muscle growth, neurodevelopmental disorders, and metabolic pathways.

## Interactions
FBXO40 is a muscle-specific E3 ubiquitin ligase that is part of the SCF (Skp1-Cullin 1-F-box) complex. It plays a crucial role in the ubiquitination and degradation of IRS1 (Insulin Receptor Substrate 1) in skeletal muscle. FBXO40 physically interacts with Skp1, Cullin 1, and Rbx1 to form the SCF complex, which targets IRS1 for proteasomal degradation. This interaction is enhanced by the tyrosine phosphorylation of IRS1, facilitating its ubiquitination (Shi2011The).

The SCF-Fbxo40 complex is essential for regulating IGF1 (Insulin-like Growth Factor 1) signaling in muscle cells. The interaction between FBXO40 and IRS1 is critical for controlling the degradation of IRS1, which in turn affects downstream signaling pathways such as Akt phosphorylation. This regulatory mechanism is important for muscle growth and hypertrophy, as demonstrated by increased muscle mass and thicker myotubes upon Fbxo40 knockdown (Shi2011The).

FBXO40's role in muscle insulin metabolism is further supported by studies showing that Fbxo40 knockout mice exhibit increased IRS1 levels and muscle hypertrophy, indicating its significant impact on muscle development and maintenance (Blondelle2020The).


## References


[1. (Stefanetti2014Ageing) Renae J. Stefanetti, Evelyn Zacharewicz, Paul Della Gatta, Andrew Garnham, Aaron P. Russell, and Séverine Lamon. Ageing has no effect on the regulation of the ubiquitin proteasome-related genes and proteins following resistance exercise. Frontiers in Physiology, 2014. URL: http://dx.doi.org/10.3389/fphys.2014.00030, doi:10.3389/fphys.2014.00030. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2014.00030)

[2. (Glessner2009Autism) Joseph T. Glessner, Kai Wang, Guiqing Cai, Olena Korvatska, Cecilia E. Kim, Shawn Wood, Haitao Zhang, Annette Estes, Camille W. Brune, Jonathan P. Bradfield, Marcin Imielinski, Edward C. Frackelton, Jennifer Reichert, Emily L. Crawford, Jeffrey Munson, Patrick M. A. Sleiman, Rosetta Chiavacci, Kiran Annaiah, Kelly Thomas, Cuiping Hou, Wendy Glaberson, James Flory, Frederick Otieno, Maria Garris, Latha Soorya, Lambertus Klei, Joseph Piven, Kacie J. Meyer, Evdokia Anagnostou, Takeshi Sakurai, Rachel M. Game, Danielle S. Rudd, Danielle Zurawiecki, Christopher J. McDougle, Lea K. Davis, Judith Miller, David J. Posey, Shana Michaels, Alexander Kolevzon, Jeremy M. Silverman, Raphael Bernier, Susan E. Levy, Robert T. Schultz, Geraldine Dawson, Thomas Owley, William M. McMahon, Thomas H. Wassink, John A. Sweeney, John I. Nurnberger, Hilary Coon, James S. Sutcliffe, Nancy J. Minshew, Struan F. A. Grant, Maja Bucan, Edwin H. Cook, Joseph D. Buxbaum, Bernie Devlin, Gerard D. Schellenberg, and Hakon Hakonarson. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature, 459(7246):569–573, April 2009. URL: http://dx.doi.org/10.1038/nature07953, doi:10.1038/nature07953. This article has 1085 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature07953)

[3. (Stepanov2018Analysis) Vadim Stepanov, Kseniya Vagaitseva, Anna Bocharova, Andrey Marusin, Valentina Markova, Larisa Minaycheva, and Oksana Makeeva. Analysis of association of genetic markers in the luzp2 and fbxo40 genes with the normal variability in cognitive performance in the elderly. International Journal of Alzheimer’s Disease, 2018:1–7, 2018. URL: http://dx.doi.org/10.1155/2018/2686045, doi:10.1155/2018/2686045. This article has 5 citations.](https://doi.org/10.1155/2018/2686045)

[4. (Blondelle2020The) Jordan Blondelle, Andrea Biju, and Stephan Lange. The role of cullin-ring ligases in striated muscle development, function, and disease. International Journal of Molecular Sciences, 21(21):7936, October 2020. URL: http://dx.doi.org/10.3390/ijms21217936, doi:10.3390/ijms21217936. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21217936)

[5. (Yang2016Role) X.‐D. Yang, D.‐X. Xiang, and Y.‐Y. Yang. Role of e3 ubiquitin ligases in insulin resistance. Diabetes, Obesity and Metabolism, 18(8):747–754, May 2016. URL: http://dx.doi.org/10.1111/dom.12677, doi:10.1111/dom.12677. This article has 36 citations.](https://doi.org/10.1111/dom.12677)

[6. (Shi2011The) Jun Shi, Liqing Luo, John Eash, Chikwendu Ibebunjo, and David J. Glass. The scf-fbxo40 complex induces irs1 ubiquitination in skeletal muscle, limiting igf1 signaling. Developmental Cell, 21(5):835–847, November 2011. URL: http://dx.doi.org/10.1016/j.devcel.2011.09.011, doi:10.1016/j.devcel.2011.09.011. This article has 120 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.devcel.2011.09.011)

[7. (Rosti2013The) Rasim O Rosti, Abdelrahim A Sadek, Keith K Vaux, and Joseph G Gleeson. The genetic landscape of autism spectrum disorders. Developmental Medicine &amp; Child Neurology, 56(1):12–18, October 2013. URL: http://dx.doi.org/10.1111/dmcn.12278, doi:10.1111/dmcn.12278. This article has 73 citations.](https://doi.org/10.1111/dmcn.12278)